We are live on ! Find out more
AIM icon

AIM ImmunoTech
AIM

35 hedge funds and large institutions have $1.67M invested in AIM ImmunoTech in 2022 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 3

3% more funds holding

Funds holding: 34 → 35 (+1)

0.87% less ownership

Funds ownership: 12.02% → 11.15% (-0.87%)

29% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 7

77% less capital inflows, than outflows

Capital inflows: $59.1K | Capital outflows: $256K

Holders
35
Holders Change
+1
Holders Change %
+2.94%
% of All Funds
0.56%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
5
Reduced
7
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$32.7K
2
UBS Group
UBS Group
Switzerland
+$10.8K
3
Two Sigma Securities
Two Sigma Securities
New York
+$6.69K
4
Renaissance Technologies
Renaissance Technologies
New York
+$5.58K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$2.37K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$224K
2
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors
North Carolina
-$12K
3
LPL Financial
LPL Financial
California
-$9K
4
Millennium Management
Millennium Management
New York
-$5.2K
5
Virtu Financial
Virtu Financial
New York
-$3.72K

AIM Hedge Fund Activity: Q4 2022 in Review

35 of the 6,243 institutional investors tracked by Wall St. Rank reported a position in AIM ImmunoTech (AIM) for Q4 2022, worth a combined $1.67M — down 50% from $3.36M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new AIM positions and 3 closed out — a net gain of 2 holders — while 5 added to existing stakes and 7 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $32.7K. The largest seller was Morgan Stanley, cutting an estimated $224K.

  • 35 institutional investors held AIM ImmunoTech (AIM) as of Q4 2022, up from 34 in Q3 2022.
  • Funds reported $1.67M of AIM ImmunoTech stock for Q4 2022, down 50% quarter-over-quarter.
  • 5 funds opened new AIM ImmunoTech positions in Q4 2022 and 3 closed out, a net change of +2 holders.
  • The largest AIM ImmunoTech buyer in Q4 2022 was Citadel Advisors, an estimated $32.7K added.
  • The largest AIM ImmunoTech seller in Q4 2022 was Morgan Stanley, an estimated $224K sold.

Based on aggregated 13F filings for Q4 2022.